Intended for healthcare professionals

Letters Child influenza vaccination

Panvax febrile reactions not a predictor

BMJ 2010; 341 doi: (Published 21 July 2010) Cite this as: BMJ 2010;341:c3714
  1. Ruth Lopert, principal medical adviser1,
  2. Terry Nolan, head2
  1. 1Therapeutic Goods Administration, Symonston, ACT 2609, Australia
  2. 2Melbourne School of Population Health, University of Melbourne and Murdoch Children’s Research Institute, Parkville, VIC 3010, Australia
  1. ruth.lopert{at}

    Collignon and colleagues assert that febrile reactions seen in pandemic influenza A/H1N1 vaccine (Panvax) clinical trials were an overlooked predictor of the excess febrile reactions seen with CSL’s seasonal trivalent influenza vaccine that prompted suspension of its use in children under 5.1 Yet most febrile reactions reported in the Australian Panvax trial were mild, with severe fever (>39.5°C) in only 2%.2 Fever …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription